Finally, there is no clear consensus on whether or not the levels of sclerostin are altered in OI patients, although there is evidence of improved bone properties in several mouse models of OI (oim/oim [27], +/G610C, Brtl−/− [122], Col1a1+/Jrt [123], and Crtap−/− [124]) subjected to sclerostin inhibition. This evidence concerns the gene SOST and osteogenesis imperfecta.